Generic drugs

Shares of Mylan NV (NASDAQ: MYL) were trading higher by 0.85 percent early Tuesday morning after the company announced the launch of Linezolid Tablets, 600 mg. Linezolid is a generic version of Pfizer Inc. (NYSE: PFE)'s Zyvox Tablets and is intended for adults and children for the treatment...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) established a joint business venture with Japan-based Takeda Pharmaceutical Company at the end of November. The companies updated the investment community on Sunday and offered details of their strategic partnership. According to a joint...

The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." RBC: Slashing LinnCo Price Target Last week, John Ragozzino of RBC Capital Markets downgraded shares of LinnCo LLC (NASDAQ: LNCO) to Sector Perform...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) surged to new 52-week highs of $69.42 on Monday after the company announced its acquisition of Allergan PLC (NYSE: AGN)'s Generics segment for a total consideration of $40.5 billion. Shares of Allergan also spiked to new 52-...

In a report published Wednesday, Gabelli & Company analyst Kevin Kedra commented on Teva Pharmaceutical Industries Ltd (NYSE: TEVA)'s offer to acquire Mylan NV (NASDAQ: MYL) for $82 per share. Teva argued that the acquisition could realize $2 billion of synergies, resulting in $10 billion...

In a report published Monday, JPMorgan analyst Lisa Gill upgraded shares of Rite Aid Corporation (NYSE: RAD) to Overweight from Not Rated with a $10 price target ahead of its fourth quarter results on Wednesday. Gill noted that Rite Aid's fourth quarter report will remain "somewhat...

Meredith Adler of Barclays maintained an Equal-Weight rating on Walgreen Company (NYSE: WAG) with a price target raised to $72 from a previous $68 following the company's first quarter results. According to Adler, Walgreen's results were “ahead of expectations” and during the earnings call, the...

Robert Jones, analyst at Goldman Sachs believes that the Drug Chain stores remain an attractive investment, but Rite-Aid (NYSE: RAD) is uniquely positioned to experience greater relative growth compared to the industry as a whole. Following Rite-Aid's announcement in February that it would be...